

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **May 2025**

**Commission File Number 001-41231**

**TC BIOPHARM (HOLDINGS) PLC**

(Translation of registrant's name into English)

**Maxim 1, 2 Parklands Way  
Holytown, Motherwell, ML1 4WR  
Scotland, United Kingdom  
+44 (0) 141 433 7557**  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F     Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**Submission of Matters to a Vote of Shareholders**

The general meeting of shareholders, which was announced on May 6, 2025, was convened in accordance with the Articles of association of the Company on May 22, 2025; and, in line with the powers vested in the chairman of the meeting with the consent of the meeting, the general meeting was adjourned by the chairman indefinitely, to a time and place to be determined and announced.

---

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TC BIOPHARM (HOLDINGS) PLC**

By:           /s/ Martin Thorp          

Name: Martin Thorp

Title: Chief Financial Officer

Date: May 27, 2025

---